PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Issue 12 (December 2020)

• Record Type: Journal Article
• Authors: Tew, William P.; Lacchetti, Christina; Ellis, Annie; Maxian, Kathleen; Banerjee, Susana; Bookman, Michael; Jones, Monica Brown; Lee, Jung-Min; Lheureux, Stéphanie; Liu, Joyce F.; Moore, Kathleen N.; Muller, Carolyn; Rodriguez, Patricia; Walsh, Christine; Westin, Shannon N.; Kohn, Elise C.
• Is Part Of: Obstetrical & gynecological survey. Volume 75:Issue 12(2020)
• Publication Date: 2020-12
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/OGX.0000000000000869
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from J Clin Oncol 2020;38:3468–3493) Despite advances in diagnosis and therapy, an individual with ovaries carries an approximate 1 in 108 lifetime chance to die due to ovarian cancer (OC). Primary therapy typically involves surgical cytoreduction and a combination regimen of platinum and a taxane.